ASH 2016: Which Patients With Chronic Lymphocytic Leukemia (CLL) Become Resistant to Ibrutinib

This week I'm posting the final installment of my 3-part interview with Dr. Adrian Wiestner from the NIH where we discussed which CLL patients are more likely to relapse when being treated with ibrutinib and the options that are available if that happens. You can read my summary, and watch the interview here: cllsociety.org/2017/06/cll-...

TOMORROW, the 2nd 2017 issue of The CLL Tribune will be published. Watch your email and set aside some time to read the fantastic articles in this issue, written by both patients and CLL experts. Very cool

Stay strong.

We are all in this together.

Brian

Ibrutinib failure as a result of progressive chronic lymphocytic leukemia (CLL) or Richter's Transformation.

This week I'm posting another interview that took place at ASH 2016 with Dr. Adrian Wiestner from the NIH where we discussed ibrutinib failure as a result of progressive CLL or Richter's Transformation. You can view my summary, and watch the interview here: http://cllsociety.org/2017/06/ibrutinib-failure-prog-cll-rt/ 

We have posted interviews and articles about research that is being conducted to study treatment options for patients with relapsed or refractory CLL. On occasion we will make our readers of a clinical trial that is starting that might be of interest. Today we have posted some information about a trial for patients with relapsed refractory CLL who have received 2 or more prior treatments, including treatment with a BTK inhibitor such as ibrutinib or acalabrutinib. You can read more about it here: http://cllsociety.org/2017/06/new-clinical-trial-rr-cll/

Stay strong

We are all in this together

Brian

Monoclonal B-Cell Lymphocytosis: A precursor to CLL (chronic lymphocytic leukemia)

This week I'm posting  on the CLL Society website an interview that took place at ASH 2016 with Dr. Neil Kay from the Mayo Clinic in Rochester, MN where we discussed monoclonal B-cell lymphocytosis or MBL, which is felt to be a precursor to CLL. You can view my summary, and watch the interview here: http://cllsociety.org/2017/06/mbl-precursor-cll/

We have posted interviews and articles about research that is being conducted to study treatment options for patients with relapsed or refractory CLL. On occasion we will make our readers of a clinical trial that is starting that might be of interest. Today we have posted some information about a trial for patients with relapsed refractory CLL who have received 2 or more prior treatments, including treatment with a BTK inhibitor such as ibrutinib or acalabrutinib. You can read more about it here: http://cllsociety.org/2017/06/new-clinical-trial-rr-cll/

Our big quarterly newsletter is next week.

So much to share. So little time.

ASH 2016: Dr. Seymour on combination therapies for chronic lymphocytic leukemia (CLL)

Combination therapies are the future in CLL. And combinations that include venetoclax are being actively researched.

For good reasons. Venetoclax is a potent drug and a potential closer, wiping the blood and marrow clean of CLL.  Or at least to a level so low that the cancerous clone can't be found.

This week I'm posting on the CLL Society website an interview with Dr. John Seymour from the Peter MacCallum Cancer Centre in Melbourne, Australia when we talked at ASH 2016 about combination therapy with venetoclax. You can view my summary, watch the interview or read the transcript at http://cllsociety.org/20…/…/ash-2016-venetoclax-combination/.

For those of you who didn't catch this last week, check out the new 2 minute video I posted about helping to fulfill the mission of the CLL Society. You can view it at http://cllsociety.org/donate-to-cll-society/. We are so thankful to those of you who provided feedback and support us.

Stay strong

Brian

PS: I will be posting a personal update here very soon.

ASH 2016: Dr. Anthony Mato on Real world Data on CLL (chronic lymphocytic leukemia)

I've posted on CLLSociety.org an interview with Dr. Anthony Mato from U. Penn when we talked at ASH 2016 about the real-world research he has been doing patients being treated with ibrutinib both in the community and academic settings, and not just within clinical trials. 

You can view my summary, watch the interview or read the transcript here.

Real world data is an important and challenging growing area of research, not just in CLL bit across many diseases

Here is a link to an interview with former FDA commissioner Robert Califf, MD discussing the pros and cons of real world data and best practices for research.

I am very fortunate to be working with Dr. Mato on our CLL patient journey research survey.

More on Genetic Testing in CLL in A Facebook Live Event at 1 PM June 1

A genetic testing Facebook Live event this Thursday from ASCO with Dr. Jeffrey Jones similar to the one I did at iwCLL. 

Dr. Jones from Ohio State University (OSU )is a great educator.

The link to the OSUCCC Facebook page where the event will take place is here: https://www.facebook.com/OSUCCCJames/

Event Details:

Dr. Jeffrey Jones will discuss genetic testing in CLL from the Ohio State University Comprehensive Cancer Center (OSUCCC) Facebook page live from the ASCO meeting.

Thursday, June 1

2:30 PM CT